Healthcare entity
All 1 tracked stories fall under one category: acquisition. Ambros Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Neridronate appears in 1 tracked Healthcare story from August 22, 2026. The tracked stories average 2 original sources each.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: acquisition. Ambros Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Neridronate appears in 1 tracked Healthcare story from August 22, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Neridronate. Shared-story counts are live from our verified record — not editorial picks.
Cash runway into first half of 2029
Proceeds from the $150 million private placement are expected to fund a planned NDA submission and operations into the first half of 2029.
CRPS-RISE Phase 3 topline results expected
Ambros expects to report topline results from the pivotal CRPS-RISE trial evaluating neridronate in warm CRPS-1.
Merger and $150M financing announced
Werewolf Therapeutics and Ambros Therapeutics announce a definitive all-stock merger and an oversubscribed $150 million private placement.
The Werewolf-Ambros merger creates a Nasdaq-listed company focused on neridronate for CRPS-1, an under-served pain indication affecting 65,000 newly diagnosed U.S. patients yearly. A $150 million financing funds a 270-patient pivotal Phase 3 trial with topline data expected in 2028.
Source: rttnews.com · Investing South Africa
Neridronate is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
